Renal biomarkers facilitate in identifying or diagnosing the patients in the possibility of creating kidney diseases, by evaluating their urine otherwise blood levels. These are regularly discharged in chronic or acute kidney damage which is described by the quick or slow breakdown of kidney function resulting in serious clinical consequences. There is an approaching prerequisite for sensitive and particular biomarkers that may distinguish kidney diseases at the earliest. The early detection makes convenient preventive steps before the harm becomes noticeably permanent.
The overall market for the renal biomarker is anticipated to exhibit a 7.0% CAGR throughout the assessment period of 2016–2026 and will reach a market valuation of approximately US$ 1,770.3 Million in terms of revenue through the end of 2026.
The overall market ON the basis of biomarker type is divided into up-regulated proteins (neutrophil gelatinase-associated lipocalin interleukin 18 and kidney injury molecule 1), functional biomarker (urine albumin, serum cystatin C and serum creatinine) and others. The up-regulated proteins division was estimated to gain 33.8% of the overall market share in value terms through 2016 end. The functional biomarker division was expected to capture 52.3% of the overall market value share through the end of 2016 and is likely to hold its dominance all through the projected period.
Based on the diagnostic technique, the overall market is segmented into enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay, chemiluminescent enzyme immunoassay and liquid chromatography-mass spectrometry colorimetric assay. The enzyme-linked immunosorbent assay is estimated to be the largest segment and will be recording a robust 8.1% CAGR all through the assessment period 2016-2026. The particle-enhanced turbidimetric immunoassay is projected to be the second biggest segment in value terms and retained a 21.0% of overall market value share during 2016 end.
The overall market on the basis of the end user is categorized into diagnostic labs, outpatient clinics, hospitals and research centres. The Diagnostic Labs accounted for about 34.2% of the overall market share in revenue terms during 2016 and is predicted to register huge growth all through the predicted period. The outpatient clinics are expected to record a 7.2% CAGR all through the considered period.
The overall market on the basis of the region is analyzed across Asia Pacific excluding Japan, Japan, Eastern Europe, Western Europe, Latin America, North America and Middle East and Africa. North America was expected to retain 32.2% of the overall revenue market share through 2016 end. Western Europe was anticipated to retain the second biggest market share of 21.1% in the course of 2016.
Key Market Players
Some of the prominent companies functional in the overall market for renal biomarker include: Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Thermo Fisher Scientific Inc., Randox Laboratories Ltd., BIOPORTO A/S, Astute Medical Inc.
Queries regarding these research findings can be addressed to Future Market Insights’ analysts at firstname.lastname@example.org